<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58383">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02345980</url>
  </required_header>
  <id_info>
    <org_study_id>Sildenafil and USS</org_study_id>
    <nct_id>NCT02345980</nct_id>
  </id_info>
  <brief_title>Is There a Role of Phosphodiesterase 5 Inhibitor (Sildenafil) in Relieving Ureteral Stent Related Symptoms, RCT</brief_title>
  <official_title>Is There a Role of Phosphodiesterase 5 Inhibitor (Sildenafil) in Relieving Ureteral Stent Related Symptoms: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite its beneficial effect, ureteral stents may produce lower urinary tract symptoms
      (such as dysuria, frequency, urgency, urge incontinence and suprapubic pain) that affect the
      quality of life and sexual health in 70-80%.

      This study will be conducted to evalute the role of Phosphodiestrase 5 inhibitor
      (Sildenafil) in relieving these symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patient: Patient who will undergo ureteral stent fixation after endoscopic procedures

      Inclusion criteria:

        1. Patient aged from 20-50 years.

        2. Sexually active. .Exclusion criteria:

      1. Patients who had LUTS before stent fixation. 2. Ureteral stent fixation after open
      surgery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single Blind (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the ureteral stent symptoms questionnaire total score</measure>
    <time_frame>one year</time_frame>
    <description>show the difference of the total score and every section score in patient received Sildenafil and placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Is it safe to patient with ureteral stent to received Sildenafil</measure>
    <time_frame>one year</time_frame>
    <description>analyse the side effect of the drug on patient and if they get benefit or not.this analysis based on VAS and The IIEF-5 Questionnaire (SHIM)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient in this arm will recieve sildinafil 50 mg tablet once daily after ureteral stent fixation for 2 weeks .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient in this arm will recieve Placebo daily after ureteral stent fixation for 2 weeks .</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil</intervention_name>
    <description>Patients in this arm will receive Sildenafil 50 tablet daily from fixation of the stent for 2 weeks</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient aged from 20-50 years

          2. Sexually active

        Exclusion Criteria:

          1. Patients who had LUTS before DJ stent fixation

          2. DJ stent fixation after open surgery
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed A Tharwat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Urology and Nephrology Center, Mansoura University, Egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed A Tharwat, MD</last_name>
    <phone>020502262222</phone>
    <email>tharwat_m3@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed R EL-Nahas, MD</last_name>
    <phone>00201221136899</phone>
    <email>ar_el_nahas@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Urology and Nephrology Center, Mansoura University</name>
      <address>
        <city>Mansoura</city>
        <zip>35516</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed A Tharwat, MD</last_name>
      <phone>0020502262222</phone>
      <email>tharwat_m3@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ahmed A EL-Nahas, MD</last_name>
      <phone>00201221136899</phone>
      <email>ar_el_nahas@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 23, 2015</lastchanged_date>
  <firstreceived_date>October 1, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>mohamed awad tharwat</investigator_full_name>
    <investigator_title>Urology &amp; Nephrology Center</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Phosphodiesterase 5 Inhibitors</mesh_term>
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
